HSIC henryschein.com: EV/EBITDA Multiple

Public company logo of henryschein.com (HSIC)

A steady inflow of funds from medical supply deliveries supports Henry Schein, Inc. (HSIC) while management addresses the aftermath of a cyberattack. The company's EV/EBITDA chart clearly demonstrates this trend, where the 12.96 mark records this metric. Financial stability is based on bulk B2B procurement of consumables and software by independent dental clinics and laboratories worldwide.

Henry Schein Corp - HSIC Company Value to EBITDA (period 11/23/2025 - 11/12/2026)

Comprehensive metric breakdowns and analytics for henryschein.com (HSIC)

- stock price and consensus target price:
Stock Quotes Henry Schein Corp|HSIC - Average Forecast Price
- company stock capitalization data:
Market Capitalization Henry Schein Dental|HSIC - Value Adjusted for Debt and Cash
- issuer book value statistics:
Book Value per Share Henry Schein|HSIC - Total Stockholders' Equity|Market Value to Book Value Ratio henryschein.com|HSIC - Total Business Assets
- debt and solvency information:
Debt to Equity Henry Schein, Inc.|HSIC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Henry Schein|HSIC - Company Cumulative Debt|Debt to Book Value Henry Schein Dental|HSIC - Company Long-Term Loans and Borrowings|Company Short-Term Debt Henry Schein|Quick Ratio henryschein.com
- financial results and valuation multiples details:
HSIC - Net Income|Projected Future Earnings Henry Schein, Inc.|HSIC - Company Value to Net Income|Forward P/E Multiple Henry Schein, Inc.|HSIC - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Henry Schein Dental|HSIC - Operating income before deduction of amortization|Earnings per share for the last twelve months Henry Schein|HSIC - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months henryschein.com|HSIC - Earnings per share increase in current year|Earnings growth forecast for next year Henry Schein, Inc.
Initial company analysis:Henry Schein Corp (HSIC)
Original product of Henry Schein Inc

The EV/EBITDA multiple determines the value of a business relative to its operating profit, combining market capitalization and net debt to eliminate the impact of tax regimes. By analyzing the change in the EV/EBITDA value over time, an investor assesses the premium paid for the assets of Henry Schein, Inc. (HSIC), whose resilience is based on stable demand from medical clinics and a predictable cash flow.

Key competitors

CVS Health - Enterprise Value to EBITDA Ratio|McKesson Group (MCK) - Company Value to EBITDA|Cencora, Inc. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CAH (cardinalhealth.com)|PBH: EV/EBITDA Multiple|Company Value to EBITDA Wellgistics Health (WGRX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 111, Inc|Enterprise Value to Operating Income Before Depreciation RDGT (Jiuzhou 360)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Universe Pharmaceuticals (UPC)|BDRX (biodexapharma.com) - Business Value to Operating Income Before Depreciation|Hong Kong Pharma Digital Limited - Enterprise Value to EBITDA Ratio|BIMI Holdings, Inc. (BIMI) - Company Value to EBITDA|CJJD: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation WBA (Walgreens Boots Alliance)